Virus weapon targets advanced rectal cancer in new trial
NCT ID NCT06459869
Summary
This early-stage trial is testing the safety and initial effectiveness of a new drug called NG-350A when given alongside standard chemoradiation for locally advanced rectal cancer. NG-350A is a modified virus designed to selectively infect and activate the immune system against the tumor. The study will enroll about 30 patients to see if this combination helps shrink tumors and is safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
AdventHealth Orlando
RECRUITINGOrlando, Florida, 32804, United States
Contact
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact
-
The Royal Marsden NHS Foundation Trust
RECRUITINGSutton, United Kingdom
Contact
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
University College London NHS FT
RECRUITINGLondon, United Kingdom
Contact
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Conditions
Explore the condition pages connected to this study.